DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for intellectual disability, FRA12A type — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntellectual disability, FRA12A type maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intellectual disability, fra12a type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment is described in these abstracts for intellectual disability, FRA12A type or any other form. The 2011 review states that intellectual disability has historically been considered immutable and that current medical practice aims only at symptom relief, not at altering cognitive deficits. It mentions the possibility that pharmaceutical therapies targeting Fragile X syndrome might become a benchmark for CNS drug discovery, but provides no data on any specific compound, no trial results, and no evidence that such therapies exist yet.
The 2019 paper concerns the Learning Disability Screening Questionnaire, a diagnostic tool, not a treatment. It reports that the questionnaire can identify adults not previously known to have an intellectual disability and may help prioritise diagnostic assessment and inform support needs. No drug is mentioned, and no therapeutic intervention is tested or proposed.
The 2022 paper argues that there is a disconnect between knowledge of mutated genes in intellectual disability and understanding of the molecular mechanisms. It calls for elucidating signalling and transcriptional networks to afford new therapeutic opportunities, but presents no experimental data, no drug candidates, and no clinical results. No specific therapy is validated or tested.
What is still missing: any clinical trial of a drug for FRA12A-type intellectual disability, any preclinical model specific to FRA12A, any patient stratification strategy, and any funding directed toward this particular genetic subtype. The abstracts offer only general aspirations and a screening questionnaire, not a treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
ACS Chemical Neuroscience · 2011 · 19 citations · open access
Fragile X Syndrome: An Update on Developing Treatment Modalities
AbstractIntellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.
Journal of Applied Research in Intellectual Disabilities · 2019 · 10 citations · open access
The impact of an adult intellectual disability screening questionnaire on service providers and users
AbstractBACKGROUND: One contributor to the health inequalities that people with an intellectual disability face is failure to identify their intellectual disability. The Learning Disability Screening Questionnaire (LDSQ) can identify adults who are likely to have an intellectual disability, but little is known about its impact. METHODS: A modified Delphi approach (literature search, interviews with staff and those using services [n = 28], and completion of an online survey by professionals [n = 29]) was used to develop a framework to evaluate the impact of the LDSQ. RESULTS: Items endorsed by 60% or more of respondents (9/18) were included in the final framework. These all related to benefits of the LDSQ, including identifying people not previously known to have an intellectual disability; helping prioritize diagnostic assessment; informing support needs; and helping increase wellbeing and life chances. CONCLUSION: The LDSQ may offer one way of helping address the health inequalities that people with an intellectual disability face.
Therapeutic validation and targeting of signalling networks that are dysregulated in intellectual disability
AbstractIntellectual disability (ID) represents a major burden on healthcare systems in the developed world. However, there is a disconnect between our knowledge of genes that are mutated in ID and our understanding of the underpinning molecular mechanisms that cause these disorders. We argue that elucidating the signalling and transcriptional networks that are dysregulated in patients will afford new therapeutic opportunities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
